Literature DB >> 32728120

Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model.

Masaki Yamazaki1, Atsuhiko Kato2, Eiji Oki3, Yoko Zaitsu3, Chie Kato2, Kiyotaka Nakano4, Miho Nakamura4, Takuya Sakomura4, Shigeto Kawai4, Etsuko Fujii2,4, Noriaki Sawada2, Takeshi Watanabe5, Hiroshi Saeki3, Masami Suzuki2,4.   

Abstract

New cancer characteristics can be discovered by focusing on the process of tumor formation. Cancer stem cells (CSCs) are a key subpopulation, as they are theorized to be at the apex of the tumor hierarchy. We can better understand their function in the tumor hierarchy by using sectioned samples to observe the growth of tumors from their origins as CSCs. In this study, we evaluated the growth of moderate differentiated colorectal cancer from LGR5-positive cells, which is a CSC marker of colorectal cancer, using xenograft and three-dimensional culture models spatiotemporally. These cells express LGR5 at high levels and show CSC phenotypes. To detect them, we used a previously generated antibody that specifically targets LGR5, and were therefore able to observe LGR5-positive cells aggregating into small clusters (sCLs) over the course of tumor growth. Because these LGR5-expressing sCLs formed continuously during growth mainly in the invasive front, we concluded that the structure must contribute significantly to the expansion of CSCs and to tumor growth overall. We confirmed the formation of sCLs from gland structures using a three-dimensional culture model. In addition, sCLs exhibited upregulated genes related to stress response and partial/hybrid epithelial-mesenchymal transition (EMT), as well as genes reported to be prognosis factors. Finally, sCLs with high LGR5 expression were identified in clinical samples. Based on these results, we elucidate how sCLs are an important contributors to tumor growth and the expansion of CSCs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32728120     DOI: 10.1038/s41374-020-0471-y

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  44 in total

Review 1.  A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms.

Authors:  Monica Cojoc; Katrin Mäbert; Michael H Muders; Anna Dubrovska
Journal:  Semin Cancer Biol       Date:  2014-06-20       Impact factor: 15.707

Review 2.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

3.  Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.

Authors:  L Vermeulen; M Todaro; F de Sousa Mello; M R Sprick; K Kemper; M Perez Alea; D J Richel; G Stassi; J P Medema
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

4.  Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells.

Authors:  Kristel Kemper; Pramudita R Prasetyanti; Wim De Lau; Hans Rodermond; Hans Clevers; Jan Paul Medema
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

5.  LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.

Authors:  Xing Gong; Ali Azhdarinia; Sukhen C Ghosh; Wei Xiong; Zhiqiang An; Qingyun Liu; Kendra S Carmon
Journal:  Mol Cancer Ther       Date:  2016-05-20       Impact factor: 6.261

6.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

Review 7.  Cancer stem cells revisited.

Authors:  Eduard Batlle; Hans Clevers
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

Review 8.  Recent Advances in Lgr5+ Stem Cell Research.

Authors:  Carly Leung; Si Hui Tan; Nick Barker
Journal:  Trends Cell Biol       Date:  2018-02-21       Impact factor: 20.808

9.  Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.

Authors:  Melissa R Junttila; Weiguang Mao; Xi Wang; Bu-Er Wang; Thinh Pham; John Flygare; Shang-Fan Yu; Sharon Yee; David Goldenberg; Carter Fields; Jeffrey Eastham-Anderson; Mallika Singh; Rajesh Vij; Jo-Anne Hongo; Ron Firestein; Melissa Schutten; Kelly Flagella; Paul Polakis; Andrew G Polson
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

Review 10.  Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?

Authors:  R G Morgan; E Mortensson; A C Williams
Journal:  Br J Cancer       Date:  2018-05-30       Impact factor: 7.640

View more
  2 in total

1.  Protruding structures with high expression of LGR5 are formed during regrowth phase after chemo-treatment in xenograft model of colorectal adenocarcinoma.

Authors:  Masaki Yamazaki; Atsuhiko Kato; Noriaki Sawada; Takeshi Watanabe; Masami Suzuki
Journal:  Histol Histopathol       Date:  2021-09-08       Impact factor: 2.303

Review 2.  Pleiotropic effects of DCLK1 in cancer and cancer stem cells.

Authors:  Dibyashree Chhetri; Srinivasan Vengadassalapathy; Santhosh Venkadassalapathy; Varadharaju Balachandran; Vidhya Rekha Umapathy; Vishnu Priya Veeraraghavan; Selvaraj Jayaraman; Shankargouda Patil; Ashok Iyaswamy; Kanagaraj Palaniyandi; Dhanavathy Gnanasampanthapandian
Journal:  Front Mol Biosci       Date:  2022-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.